This article is for subscribers only. Isomorphic Labs, a subsidiary of Alphabet Inc., said it entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co.

Alphabet has now taken that advancement and created a new company called Isomorphic Labs, focused on AI-driven drug discovery. This commercial venture was founded and is currently led by DeepMind ...

The latest to do so is Google parent company Alphabet, which has established Isomorphic Labs, under DeepMind head Demis Hassabis, to take its shot at the promising new field.

Now we have a better idea with Alphabet announcing the creation of a new subsidiary called Isomorphic Labs. The company states its goal is to “reimagine” the process of developing new drugs ...

Alphabet has created a new subsidiary called Isomorphic Labs that will focus on using AI processes to develop new drugs. An offshoot from Deepmind, another AI subsidiary of Alphabet, the idea for ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design ...

Alphabet has spun off a new company called Isomorphic Labs which seeks to use artificial intelligence to discover new pharmaceutical drugs. The commercial venture will reportedly build off of ...

Google parent company Alphabet has launched a new drug discovery company in the U.K. called Isomorphic Labs. The company will build on research carried out by London artificial intelligence lab ...

Google parent company Alphabet is launching a new company called Isomorphic Laboratories which will use AI tools for drug discovery. It will build off the protein folding work from DeepMind.

Dubbed Isomorphic Labs, the commercial venture plans to build off Alphabet's DeepMind AI research incubator, and it shares that venture's founder and CEO, Demis Hassabis.

In July, the company published a paper describing AlphaFold2, open-sourced the code, and dropped a library of 350,000 protein structures with a promise to add 100 million more. This week, Alphabet ...